Amgen Inc (AMGN) stock
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3026% above fair value
$457.93−4.39 (-0.95%)
Close on Nov 17, 2026Market cap $247.57BP/E 26.5Yield 2.11%
Amgen operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Amgen's operating cash flow for the twelve months ending Sep 30, 2026 was $12.04B, down 8.3% year over year. For fiscal 2025 it was $9.96B, down 13.3% from the year before. Over ten years it grew 0.2% a year on average. The highest annual figure on record is $11.49B in fiscal 2024.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.96B | -13.3% |
| FY2024 | Dec 31, 2024 | $11.49B | +35.6% |
| FY2023 | Dec 31, 2023 | $8.47B | -12.9% |
| FY2022 | Dec 31, 2022 | $9.72B | +5.0% |
| FY2021 | Dec 31, 2021 | $9.26B | -11.8% |
| FY2020 | Dec 31, 2020 | $10.50B | +14.7% |
| FY2019 | Dec 31, 2019 | $9.15B | -19.0% |
| FY2018 | Dec 31, 2018 | $11.30B | +1.1% |
| FY2017 | Dec 31, 2017 | $11.18B | +7.9% |
| FY2016 | Dec 31, 2016 | $10.35B | +6.4% |
| FY2015 | Dec 31, 2015 | $9.73B | +8.7% |
| FY2014 | Dec 31, 2014 | $8.95B | +42.3% |
| FY2013 | Dec 31, 2013 | $6.29B | +7.0% |
| FY2012 | Dec 31, 2012 | $5.88B | +14.9% |
| FY2011 | Dec 31, 2011 | $5.12B | -11.5% |
| FY2010 | Dec 31, 2010 | $5.79B | -8.7% |
| FY2009 | Dec 31, 2009 | $6.34B | +5.8% |
| FY2008 | Dec 31, 2008 | $5.99B | +10.9% |
| FY2007 | Dec 31, 2007 | $5.40B | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $4.24B | -9.5% |
| Q2 FY2026 | Jun 30, 2026 | $4.00B | +75.5% |
| Q1 FY2026 | Mar 31, 2026 | $2.19B | +57.4% |
| Q4 FY2025 | Dec 31, 2025 | $1.60B | -66.4% |
| Q3 FY2025 | Sep 30, 2025 | $4.68B | +31.2% |
| Q2 FY2025 | Jun 30, 2025 | $2.28B | -7.3% |
| Q1 FY2025 | Mar 31, 2025 | $1.39B | +101.9% |
| Q4 FY2024 | Dec 31, 2024 | $4.77B | +786.8% |
| Q3 FY2024 | Sep 30, 2024 | $3.57B | +29.4% |
| Q2 FY2024 | Jun 30, 2024 | $2.46B | -40.2% |
| Q1 FY2024 | Mar 31, 2024 | $689.00M | -35.2% |
| Q4 FY2023 | Dec 31, 2023 | $538.00M | -79.7% |
| Q3 FY2023 | Sep 30, 2023 | $2.76B | -7.3% |
| Q2 FY2023 | Jun 30, 2023 | $4.11B | +112.9% |
| Q1 FY2023 | Mar 31, 2023 | $1.06B | -50.8% |
| Q4 FY2022 | Dec 31, 2022 | $2.65B | -5.7% |
| Q3 FY2022 | Sep 30, 2022 | $2.98B | +41.5% |
| Q2 FY2022 | Jun 30, 2022 | $1.93B | -10.4% |
| Q1 FY2022 | Mar 31, 2022 | $2.16B | -35.7% |
| Q4 FY2021 | Dec 31, 2021 | $2.81B | -1.2% |
| Q1 FY2021 | Mar 31, 2021 | $2.10B | -1.4% |
| Q4 FY2020 | Dec 31, 2020 | $2.15B | +52.3% |
| Q3 FY2020 | Sep 30, 2020 | $3.37B | +82.5% |
| Q2 FY2020 | Jun 30, 2020 | $2.84B | -11.0% |
| Q1 FY2020 | Mar 31, 2020 | $2.13B | -34.8% |
| Q2 FY2019 | Jun 30, 2019 | $1.41B | -32.7% |
| Q1 FY2019 | Mar 31, 2019 | $1.85B | -32.3% |
| Q4 FY2018 | Dec 31, 2018 | $3.19B | +6.0% |
| Q3 FY2018 | Sep 30, 2018 | $3.27B | -5.2% |
| Q2 FY2018 | Jun 30, 2018 | $2.10B | -9.6% |
| Q1 FY2018 | Mar 31, 2018 | $2.73B | +14.3% |
| Q4 FY2017 | Dec 31, 2017 | $3.01B | -2.8% |
| Q3 FY2017 | Sep 30, 2017 | $3.45B | +29.8% |
| Q2 FY2017 | Jun 30, 2017 | $2.33B | -13.1% |
| Q1 FY2017 | Mar 31, 2017 | $2.39B | – |
| Q4 FY2016 | Dec 31, 2016 | $3.10B | – |
| Q3 FY2016 | Sep 30, 2016 | $2.66B | – |
| Q2 FY2016 | Jun 30, 2016 | $2.68B | – |
See a number that looks wrong?